卡托普利对冠心病介入治疗患者心室重构及炎性因子的影响

Effects of Captopril on Ventricular Remodeling and Inflammatory Factors in Patients with Coronary Heart Disease Undergoing Interventional Therapy

目的探讨卡托普利对冠心病(CHD)介入治疗患者心室重构及炎性因子的影响。方法收集我院自2017年7月~2018年8月收治的72例接受经皮冠状动脉介入(PCI)治疗的CHD患者,按随机数字表法分为对照组和观察组,各36例。对照组术后采取常规基础治疗,观察组在对照组基础上联合卡托普利治疗,比较两组治疗前后左心室收缩末期容积(LVESV)、左室射血分数(LVEF)及血清肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)水平变化情况。结果治疗后,观察组LVEDV为(100.50±5.42)ml、LVESV为(51.05±4.11)ml,低于对照组的(110.84±7.80)ml、(64.73±5.47)ml,观察组LVEF为(60.54±4.28)%,高于对照组的(51.62±4.01)%(P<0.05);观察组血清TNF-α、IL-6水平低于对照组(P<0.05)。结论卡托普利能够有效减轻冠心病介入术后患者机体炎症反应,逆转心室重构,改善预后。

Objective To investigate the effects of captopril on ventricular remodeling and inflammatory factors in patients with coronary heart disease(CHD).Methods 72 patients with CHD who underwent percutaneous coronary intervention(PCI)from July 2017 to August 2018 were enrolled.The patients were divided into control group and observation group according to the random number table,36 cases for each group.The control group received routine basic treatment after operation.The observation group was treated with captopril on the basis of the control group.The left ventricular end-systolic volume(LVESV),left ventricular ejection fraction(LVEF)and serum tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)levels were compared before and after treatment.Results After treatment,the LVEDV of the observation group was(100.50±5.42)ml,and the LVESV was(51.05±4.11)ml,which was lower than that of the control group(110.84±7.80)ml,(64.73±5.47)ml,and the observation group LVEF was(60.54±4.28)%was higher than that of the control group(51.62±4.01)%(P<0.05);the serum levels of TNF-αand IL-6 in the observation group were lower than those in the control group(P<0.05).Conclusion Captopril can effectively alleviate the inflammatory response of patients with coronary heart disease after intervention,reverse ventricular remodeling and improve prognosis.